We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quest Diagnostics (DGX) New Pact to Boost Laboratory Services
Read MoreHide Full Article
Quest Diagnostics (DGX - Free Report) recently entered into a strategic agreement with NewYork-Presbyterian to extend access to quality, advanced laboratory services for the providers and patients. The agreement targets to serve NewYork-Presbyterian's providers and patients in the greater New York region and beyond.
The latest development is likley to broaden Quest Diagostics' laboratory services offering.
About NewYork-Presbyterian
NewYork-Presbyterian is one of the nation's largest and most comprehensive integrated academic healthcare systems, comprising 10 hospitals and campuses in New York, nearly 200 primary and specialty care clinics and medical groups and a range of telemedicine services.
More on the News
Per the definitive agreement, Quest Diagnostics will obtain lab assets in New York City and the Tri-State Area, while NewYork-Presbyterian will continue to own and operate hospital lab services, including its anatomic pathology services.
The companies expect to close the transaction in the second quarter of 2023, subject to pending customary regulatory approvals. Financial details of the transaction were kept under wraps.
Strategic Efforts
Per Quest Diagnostics’ management, Quest Diagnostics and NewYork-Presbyterian have a keen focus on the patient, deep roots in New York and reputations nationwide and beyond for better healthcare services. The agreement is intended to leverage Quest Diagnostics’ ability to offer advanced and quality clinical laboratory services.
Image Source: Zacks Investment Research
Moreover, Quest Diagnostics and NewYork-Presbyterian share a common belief that excellent patient care should be accessible to all. Both companies are determined that the agreement will enable the patients greater access to advanced, quality laboratory services.
Industry Prospects
Per a report by Grand View Research, the global clinical laboratory service market size was $201.94 billion in 2021 and is expected to register a CAGR of 3.7% by 2030. The increasing burden of chronic diseases and the growing demand for early diagnostic tests fuel the market.
Recent Developments
In December 2022, Quest Diagnostics entered into a strategic collaboration intended to extend access to advanced, quality and economical laboratory services fueling affordable care for communities in Maine. Upon completing the transaction, the collaboration will allow physicians and patients throughout Maine to get an advantage from access to Quest Diagnostic's industry-leading and highly advanced test menu, broad health plan coverage and lower costs for many services.
In November 2022, Quest Diagnostics acquired select assets of LabCare Plus — the outreach laboratory services business of Summa Health — a large integrated health system. With the buyout, the company expands access to diagnostic advancement and insights, empowering better health for more communities in Northeastern Ohio.
Price Performance
Shares of the company have gained 10.3% in the past six months against the industry’s fall of 14.3%.
Zacks Rank and Key Picks
Currently, Quest Diagnostics carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 3.3%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 10.9%.
AMN Healthcare has lost 2.2% compared with the industry’s 23.2% decline in the past year.
Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.6%. CAH’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average beat being 6.4%.
Cardinal Health has gained 44.4% against the industry’s 6.2% decline in the past year.
Merit Medical, flaunting a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.4%.
Merit Medical has gained 18.6% against the industry’s 6.2% decline in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Quest Diagnostics (DGX) New Pact to Boost Laboratory Services
Quest Diagnostics (DGX - Free Report) recently entered into a strategic agreement with NewYork-Presbyterian to extend access to quality, advanced laboratory services for the providers and patients. The agreement targets to serve NewYork-Presbyterian's providers and patients in the greater New York region and beyond.
The latest development is likley to broaden Quest Diagostics' laboratory services offering.
About NewYork-Presbyterian
NewYork-Presbyterian is one of the nation's largest and most comprehensive integrated academic healthcare systems, comprising 10 hospitals and campuses in New York, nearly 200 primary and specialty care clinics and medical groups and a range of telemedicine services.
More on the News
Per the definitive agreement, Quest Diagnostics will obtain lab assets in New York City and the Tri-State Area, while NewYork-Presbyterian will continue to own and operate hospital lab services, including its anatomic pathology services.
The companies expect to close the transaction in the second quarter of 2023, subject to pending customary regulatory approvals. Financial details of the transaction were kept under wraps.
Strategic Efforts
Per Quest Diagnostics’ management, Quest Diagnostics and NewYork-Presbyterian have a keen focus on the patient, deep roots in New York and reputations nationwide and beyond for better healthcare services. The agreement is intended to leverage Quest Diagnostics’ ability to offer advanced and quality clinical laboratory services.
Image Source: Zacks Investment Research
Moreover, Quest Diagnostics and NewYork-Presbyterian share a common belief that excellent patient care should be accessible to all. Both companies are determined that the agreement will enable the patients greater access to advanced, quality laboratory services.
Industry Prospects
Per a report by Grand View Research, the global clinical laboratory service market size was $201.94 billion in 2021 and is expected to register a CAGR of 3.7% by 2030. The increasing burden of chronic diseases and the growing demand for early diagnostic tests fuel the market.
Recent Developments
In December 2022, Quest Diagnostics entered into a strategic collaboration intended to extend access to advanced, quality and economical laboratory services fueling affordable care for communities in Maine. Upon completing the transaction, the collaboration will allow physicians and patients throughout Maine to get an advantage from access to Quest Diagnostic's industry-leading and highly advanced test menu, broad health plan coverage and lower costs for many services.
In November 2022, Quest Diagnostics acquired select assets of LabCare Plus — the outreach laboratory services business of Summa Health — a large integrated health system. With the buyout, the company expands access to diagnostic advancement and insights, empowering better health for more communities in Northeastern Ohio.
Price Performance
Shares of the company have gained 10.3% in the past six months against the industry’s fall of 14.3%.
Zacks Rank and Key Picks
Currently, Quest Diagnostics carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Merit Medical Systems, Inc. (MMSI - Free Report) .
AMN Healthcare, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 3.3%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 10.9%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare has lost 2.2% compared with the industry’s 23.2% decline in the past year.
Cardinal Health, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.6%. CAH’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average beat being 6.4%.
Cardinal Health has gained 44.4% against the industry’s 6.2% decline in the past year.
Merit Medical, flaunting a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average beat being 25.4%.
Merit Medical has gained 18.6% against the industry’s 6.2% decline in the past year.